Pricing Log in Create free account
Saturday 17 October 2026 Export RGEN’s income statement to Excel — free account

Repligen Corporation

RGEN Healthcare Medical Instruments & Supplies

Repligen Corporation’s revenue for fiscal 2025 (year ended December 2025) was $738.3 million, up 16.4% from fiscal 2024. In the quarter to June 2026, revenue grew 11.9%, EPS fell 65.4%, free cash flow grew 27.1% and total debt rose 3.25%, each against the same quarter a year earlier.

175.20 8.97 −4.87%
Market cap
$11.7B
P/E
234×
Fwd P/E
112×
Dividend yield
—
F-score
6/9
Altman Z
7.49
Beneish M
−2.52
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Repligen Corporation (RGEN) Business Profile

Updated before January 2025

Company Overview

Repligen Corporation (NASDAQ: RGEN) is a global life sciences company that specializes in bioprocessing technologies and solutions. Founded in 1981 and headquartered in Waltham, Massachusetts, Repligen has evolved from its origins as a biotechnology research company into a leading provider of innovative tools and technologies for the biopharmaceutical industry. The company is led by Tony J. Hunt, who has served as President and Chief Executive Officer since 2015. Under his leadership, Repligen has experienced significant growth, driven by strategic acquisitions, product innovation, and a focus on operational excellence.

Repligen operates globally, with manufacturing facilities and offices in the United States, Europe, and Asia. The company serves a diverse customer base, including biopharmaceutical companies, contract development and manufacturing organizations (CDMOs), and academic institutions. Repligen’s mission is to enable the advancement of life-saving therapies by providing high-quality bioprocessing solutions that improve efficiency and scalability.

Core Business Segments

Repligen’s business is organized into several core segments, each focused on providing specialized products and services for bioprocessing applications. These segments include:

1. Filtration

Repligen is a leader in filtration technologies, offering a range of products designed to improve the efficiency of bioprocessing workflows. Key products in this category include:

  • XCell™ ATF Systems: Advanced tangential flow filtration systems used for cell culture clarification and concentration.
  • TangenX™ Flat Sheet Cassettes: High-performance ultrafiltration and microfiltration cassettes for downstream processing.

2. Chromatography

Repligen provides innovative chromatography solutions that enhance the purification of biologics. Key offerings include:

  • OPUS® Pre-packed Columns: Ready-to-use chromatography columns that simplify and accelerate purification processes.
  • Affinity Ligands: Custom ligands for the purification of monoclonal antibodies and other biologics.

3. Protein Analytics

Repligen’s protein analytics solutions enable precise characterization and quantification of biologics. Products in this segment include:

  • SoloVPE® System: A variable pathlength extension system for UV/Vis spectroscopy.
  • FlowVPE® System: A flow-based variable pathlength extension system for real-time protein concentration measurement.

4. Process Analytics

Repligen offers advanced process analytics tools to monitor and optimize bioprocessing workflows. Key products include:

  • KrosFlo® Systems: Tangential flow filtration systems for process development and manufacturing.
  • Spectroscopy Solutions: Tools for real-time monitoring of critical process parameters.

5. Custom Solutions

Repligen also provides custom bioprocessing solutions tailored to the specific needs of its customers. These solutions include custom chromatography resins, filtration systems, and single-use technologies.

Business Model

Repligen’s business model is centered on providing high-value, innovative solutions that address the evolving needs of the biopharmaceutical industry. The company generates revenue through the sale of products, licensing agreements, and service contracts. Repligen’s approach to business is characterized by:

  • Customer-Centric Innovation: Developing products and technologies that solve specific challenges faced by biopharmaceutical manufacturers.
  • Strategic Acquisitions: Expanding its product portfolio and market reach through targeted acquisitions of complementary businesses.
  • Global Reach: Serving customers worldwide through a network of manufacturing facilities, sales offices, and distribution partners.

Strategic Direction

Repligen is focused on driving growth through innovation, operational excellence, and strategic investments. Key elements of the company’s strategic direction include:

  • Expansion of Product Portfolio: Developing new products and technologies to address emerging needs in bioprocessing.
  • Sustainability Goals: Implementing environmentally sustainable practices in manufacturing and product design.
  • Geographic Expansion: Increasing its presence in high-growth markets, particularly in Asia and Latin America.
  • Digital Transformation: Leveraging digital technologies to enhance product development, manufacturing, and customer engagement.

Competitive Landscape

Repligen operates in a highly competitive market, facing competition from both established players and emerging companies. Key competitors include:

  • Sartorius AG: A leading provider of bioprocessing solutions, including filtration, chromatography, and single-use technologies.
  • Thermo Fisher Scientific: A global leader in life sciences tools and services, offering a broad range of bioprocessing products.
  • Danaher Corporation: Parent company of Cytiva and Pall Corporation, both of which are major players in the bioprocessing market.
  • MilliporeSigma: The life sciences division of Merck KGaA, offering a comprehensive portfolio of bioprocessing solutions.

Risk Factors

Repligen faces several risks that could impact its business and financial performance, including:

  • Market Dependence: Reliance on the biopharmaceutical industry, which is subject to regulatory changes and market fluctuations.
  • Supply Chain Disruptions: Potential disruptions in the supply of raw materials and components used in manufacturing.
  • Competition: Intense competition from established players and new entrants in the bioprocessing market.
  • Regulatory Risks: Compliance with stringent regulatory requirements for bioprocessing products and technologies.

Recent Developments

Repligen has made significant strides in recent years, including:

  • Product Innovations: Launching new products such as advanced filtration systems and pre-packed chromatography columns.
  • Strategic Acquisitions: Acquiring companies to expand its product portfolio and market presence.
  • Global Expansion: Opening new manufacturing facilities and sales offices in key markets.
  • Sustainability Initiatives: Implementing green manufacturing practices and reducing the environmental impact of its operations.

Investment Considerations

Investors considering Repligen should weigh the following strengths and risks:

Strengths

  • Strong Market Position: Leadership in key bioprocessing segments.
  • Innovative Product Portfolio: A diverse range of high-value products and technologies.
  • Growth Potential: Opportunities for expansion in emerging markets and new product categories.

Risks

  • Market Volatility: Dependence on the biopharmaceutical industry, which is subject to economic and regulatory changes.
  • Competitive Pressure: Intense competition from established players and new entrants.
  • Operational Risks: Potential supply chain disruptions and manufacturing challenges.

Conclusion

Repligen Corporation is a leading player in the bioprocessing industry, with a strong track record of innovation and growth. The company’s focus on customer-centric solutions, strategic investments, and operational excellence positions it well for future success. While there are risks associated with market dependence and competition, Repligen’s strengths and growth potential make it an attractive option for investors seeking exposure to the life sciences sector.